The experience of directly observed therapy in Esrefpasa tuberculosis dispensary for two years Source: Eur Respir J 2005; 26: Suppl. 49, 645s Year: 2005
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006
One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007
Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Treatment patients with pulmonary tuberculosis (PT) and accompanying pathologies by DOTS strategy Source: Eur Respir J 2005; 26: Suppl. 49, 192s Year: 2005
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Impact of smoking on outcome of treatment of tuberculosis in patients taking intermittent treatment of tuberculosis under India‘s revised tuberculosis control program Source: Annual Congress 2008 - Health effects of passive smoking and of a smoking ban Year: 2008
A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
Drug resistance pattern of directly observed treatment shortcourse (DOTS) category-II relapse patients Source: Annual Congress 2011 - Tuberculosis epidemiology and public health Year: 2011
Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Directly observed therapy versus self administered therapy for patients of new smear positive pulmonary tuberculosis during hospitalisation period Source: Eur Respir J 2004; 24: Suppl. 48, 723s Year: 2004
When do we extend the treatment of tuberculosis (TB) more than 6 months? Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007
The characteristics of previous tuberculosis treatment programmes in patients with tuberculosis relapses Source: Eur Respir J 2001; 18: Suppl. 33, 473s Year: 2001
Long-term outcomes of directly observed therapy in a low tuberculosis incidence setting Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008
Treatment outcome and one year follow-up status of patients treated under DOTS category II Source: Annual Congress 2008 - Epidemiological and clinical aspects of tuberculosis control Year: 2008
Evaluation of new smear positive tuberculosis patients 5 years after initiation of treatment under a DOTS programme Source: Annual Congress 2010 - Tuberculosis epidemiology Year: 2010
Using remote directly observed therapy (R-DOT) for optimising asthma therapy. Source: International Congress 2017 – Small airways, long distances and large databases in paediatric asthma Year: 2017
Tuberculosis: follow-up of treatment without directed observed therapy (DOT) in a sanitary area Source: Eur Respir J 2004; 24: Suppl. 48, 652s Year: 2004
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
Empirical treatment for tuberculosis: survey of cases treated over a period of two years Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002